Lower lactate levels and lower intracellular pH in patients with IDH-mutant versus wild-type gliomas
KJ Wenger, JP Steinbach, O Bähr… - American Journal …, 2020 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Preclinical evidence points toward a metabolic
reprogramming in isocitrate dehydrogenase (IDH) mutated tumor cells with down-regulation …
reprogramming in isocitrate dehydrogenase (IDH) mutated tumor cells with down-regulation …
Neurochemical differences between 1p/19q codeleted and noncodeleted IDH-mutant gliomas by in vivo MR spectroscopy
F Branzoli, R Liserre, DK Deelchand, PL Poliani… - Radiology, 2023 - pubs.rsna.org
Background Noninvasive identification of glioma subtypes is important for optimizing
treatment strategies. Purpose To compare the in vivo neurochemical profiles between …
treatment strategies. Purpose To compare the in vivo neurochemical profiles between …
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas
M Zhou, Y Zhou, H Liao, BC Rowland, X Kong… - Neuro …, 2018 - academic.oup.com
Background Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-
hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the …
hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the …
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
MI de la Fuente, RJ Young, J Rubel… - Neuro …, 2015 - academic.oup.com
Background The majority of WHO grades II and III gliomas harbor a missense mutation in the
metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2 …
metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2 …
[HTML][HTML] Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with …
C Choi, JM Raisanen, SK Ganji, S Zhang… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Proton magnetic resonance spectroscopy (MRS) of the brain can detect 2-
hydroxyglutarate (2HG), the oncometabolite produced in neoplasms harboring a mutation in …
hydroxyglutarate (2HG), the oncometabolite produced in neoplasms harboring a mutation in …
In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy: No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas
KJ Wenger, E Hattingen, K Franz, J Steinbach… - Clinical …, 2019 - Springer
Purpose Previous ex vivo spectroscopic data from tissue samples revealed differences in
phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH …
phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH …
Magnetic resonance metabolic imaging of glioma
P Metellus, D Figarella-Branger - Science translational medicine, 2012 - science.org
2-Hydroxyglutarate (2-HG) is a potential oncometabolite involved in gliomagenesis that has
been identified as an aberrant product of isocitrate dehydrogenase (IDH)–mutated glial …
been identified as an aberrant product of isocitrate dehydrogenase (IDH)–mutated glial …
[HTML][HTML] A noninvasive comparison study between human gliomas with IDH1 and IDH2 mutations by MR spectroscopy
The oncogenes that are expressed in gliomas reprogram particular pathways of glucose,
amino acids, and fatty acid metabolism. Mutations in isocitrate dehydrogenase genes …
amino acids, and fatty acid metabolism. Mutations in isocitrate dehydrogenase genes …
Altered metabolic landscape in IDH‐mutant gliomas affects phospholipid, energy, and oxidative stress pathways
Heterozygous mutations in NADP‐dependent isocitrate dehydrogenases (IDH) define the
large majority of diffuse gliomas and are associated with hypermethylation of DNA and …
large majority of diffuse gliomas and are associated with hypermethylation of DNA and …
In vivo MRS measurement of 2‐hydroxyglutarate in patient‐derived IDH‐mutant xenograft mouse models versus glioma patients
Purpose To generate a preclinical model of isocitrate dehydrogenase (IDH) mutant gliomas
from glioma patients and design a MRS method to test the compatibility of 2 …
from glioma patients and design a MRS method to test the compatibility of 2 …